Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Decreases By 38.3%

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 153,293 shares, a drop of 38.3% from the July 15th total of 248,647 shares. Approximately 1.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 118,274 shares, the days-to-cover ratio is presently 1.3 days.

20/20 Biolabs Stock Performance

Shares of AIDX opened at $0.55 on Tuesday. 20/20 Biolabs has a 52-week low of $0.40 and a 52-week high of $50.00. The firm has a market cap of $6.74 million and a PE ratio of -1.97. The business’s fifty day simple moving average is $0.57.

20/20 Biolabs (NASDAQ:AIDX) last issued its earnings results on Friday, August 14th. The company reported ($0.26) EPS for the quarter. The firm had revenue of $0.73 million for the quarter.

Analyst Ratings Changes

AIDX has been the subject of several research reports. Weiss Ratings upgraded 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Maxim Group initiated coverage on 20/20 Biolabs in a research report on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.